Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT06679946
Enrolling by invitation Phase 3

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Started
2024-12-03
Last updated
2026-02-20

Condition(s) studied

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Investigational drug(s) / intervention(s)

Vutrisiran →

Vutrisiran: Vutrisiran administered SC q3M

Study summary

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003 Exclusion Criteria: * Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003 * Future or current participation in another investigational device or drug study, scheduled to occur during this study * Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation

Primary outcome measure(s)

  • Frequency of Adverse Events (AEs) — Up to 36 Months
    An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Trial sites (87)

FacilityCityRegionStatus
Clinical Trial Site Phoenix Arizona
Clinical Trial Site Beverly Hills California
Clinical Trial Site La Jolla California
Clinical Trial Site Stanford California
Clinical Trial Site Washington D.C. District of Columbia
Clinical Trial Site Chicago Illinois
Clinical Trial Site Glenview Illinois
Clinical Trial Site Indianapolis Indiana
Clinical Trial Site Kansas City Kansas
Clinical Trial Site Baltimore Maryland
Clinical Trial Site Boston Massachusetts
Clinical Trial Site Boston Massachusetts
Clinical Trial Site Rochester Minnesota
Clinical Trial Site St Louis Missouri
Clinical Trial Site Omaha Nebraska
Clinical Trial Site New York New York
Clinical Trial Site New York New York
Clinical Trial Site Durham North Carolina
Clinical Trial Site Cleveland Ohio
Clinical Trial Site Columbus Ohio
Clinical Trial Site Philadelphia Pennsylvania
Clinical Trial Site Nashville Tennessee
Clinical Trial Site Dallas Texas
Clinical Trial Site Salt Lake City Utah
Clinical Trial Site Buenos Aires Argentina
Clinical Trial Site Buenos Aires Argentina
Clinical Trial Site Buenos Aires Argentina
Clinical Trial Site Córdoba Argentina
Clinical Trial Site Rosario Argentina
Clinical Trial Site Rosario Argentina
Clinical Trial Site Rosario Argentina
Clinical Trial Site Vienna Austria
Clinical Trial Site Vienna Austria
Clinical Trial Site Aalst Belgium
Clinical Trial Site Anderlecht Belgium
Clinical Trial Site Dendermonde Belgium
Clinical Trial Site Ghent Belgium
Clinical Trial Site Hasselt Belgium
Clinical Trial Site Leuven Belgium
Clinical Trial Site Liège Belgium

+ 47 more sites — see the full list on the official registry below.

On this site

📄 Amvuttra (vutrisiran) drug profile →

More Alnylam Pharmaceuticals trials in the Netherlands

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Recruiting
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) Recruiting
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program Recruiting

Other trials for the same condition

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Recruiting
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06679946 on ClinicalTrials.gov ↗ ← All trials in the Netherlands